Litcius/Paper detail

Empagliflozin improves high-sensitive cardiac troponin-I and high-density lipoprotein cholesterol in patients with type 2 diabetes mellitus and coronary artery disease: a post-hoc analysis of EMPA-CARD Trial

Homa Taheri, Hossein Chiti, Tara Reshadmanesh, Sepehr Gohari, Ahmad Jalilvand, Shahram Arsang‐Jang, Faramarz Ismail‐Beigi, Samin Ghanbari, Mohsen Dadashi, Atieh Asgari, Mahsa Mahjani, Amir Karbalaee‐Hasani, Hassan Ahangar

2023Journal of Diabetes & Metabolic Disorders13 citationsDOIOpen Access PDF

Topics & Concepts

EmpagliflozinMedicineInternal medicineCoronary artery diseaseCardiologyPlaceboLipid profileDiabetes mellitusType 2 Diabetes MellitusMyocardial infarctionCholesterolEndocrinologyAlternative medicinePathologyDiabetes Treatment and ManagementLipid metabolism and disordersPancreatic function and diabetes
Empagliflozin improves high-sensitive cardiac troponin-I and high-density lipoprotein cholesterol in patients with type 2 diabetes mellitus and coronary artery disease: a post-hoc analysis of EMPA-CARD Trial | Litcius